← Eichor
Study identifier: NCT02169518 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Paraoxonase and HDL Qualities in Glycaemia and Inflammation

Condition: Diabetes Mellitus · Bariatric Surgery Candidate  ·  Sponsor: Manchester University NHS Foundation Trust

PhaseN/A
Planned participants600
Who can joinAll sexes, 20 Years to 75 Years
Healthy volunteersYes

About this study

The incidence of coronary heart disease (CHD) is significant in the super-obese and diabetics. Inflammation is believed to play an important part in the development of CHD, and the large collection of abdominal fat in the obese person is a vast source of inflammation. Diabetics have abnormal glucose and cholesterol metabolism which ultimately compromise their bodies' circulatory system and nerve function. Cholesterol plays a vital role in CHD. Low-density lipoprotein (LDL) particles carry cholesterol and deposit it in blood vessel walls which become damaged as a result. When LDL particles undergo changes chemically (called oxidation) or as a result of high circulating blood glucose (called glycation), they become more harmful to the body. High-density lipoprotein (HDL) particles have a protective function in CHD. Not only do they transport cholesterol away from the blood vessels to the liver to be broken down, they have properties against oxidation and inflammation. These properties are related to the activity of an enzyme on HDL called paraoxonase 1(PON1). Super-obese patients are increasingly treated by weight-reducing surgery (bariatric surgery). In this study we examine whether weight loss following bariatric surgery results in reduced inflammatory state, improved HDL function (higher PON1 activity), better control of blood glucose and less nerve damage. We will study PON1 activity, inflammation and glucose control in patients with type 1 diabetes (with and without ki…

This description comes directly from the study's public registry record.

Talk to the study team

Handrean Soran, MD FRCP  ·  01612764843  ·  hsoran@aol.com

See Kwok, MD FRCGP  ·  01612768863  ·  sk7@doctors.org.uk

Always discuss trial participation with your own doctor first.

Locations (1)

Central Manchester University Hospitals NHS Foundatioon TrustManchester, Lancashire, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02169518